
Lalocracy/iStock via Getty Images
- Veru has sold its FC2 female condom business for $18 million to a group of private investors.
- Buyers include clients of Riva Ridge Capital Management.
- As a result, Veru’s headcount will drop to 22 from 210. Estimated revenue is $12.5 million.
- It’s true he said the transaction will allow the company to focus on the development of enobosarm, its Phase 2 candidate to preserve muscle and increase fat loss in patients taking Novo Nordisk’s (NGO) Wegovy (semaglutide).
- The stock is 26% more in Tuesday morning trade.





